Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

131.95 +3.95 (+3.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
53 54 Next >
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
From Biogen Inc.
Via GlobeNewswire
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Biogen Unusual Options Activity
 
Via Benzinga
11 Analysts Have This to Say About Biogen
 
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23
Looking for longs after a clear resumption of the uptrend. 
Via Talk Markets
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
 
Via Benzinga
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States 
From Biogen Inc.
Via GlobeNewswire
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
 
Via Benzinga
Should You Buy Biogen Before a Big July Decision?
Biogen stock has dropped about 40% from its record high. 
Via The Motley Fool
Price Over Earnings Overview: Biogen
 
Via Benzinga
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
Interested in investing in iMetabolic BioPharma? Click here to get started! 
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. 
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
 
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
 
Via Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
 
Via Benzinga
Biogen's Debt Overview
 
Via Benzinga
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
It could be a make or break year for the biotech. 
Via The Motley Fool
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
From Biogen Inc.
Via GlobeNewswire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
 
Via Benzinga
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies, 
Via MarketBeat
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
 
Via Benzinga
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
The company is definitively closing the door on solanezumab. 
Via Investor's Business Daily
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule. 
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8
Looking for a bottom in wave {v} to then look for longs. 
Via Talk Markets
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.